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A B S T R A C T
Background
Dysmenorrhoea is a common gynaecological complaint that can affect as many as 50% of premenopausal women, 10% of whom
suffer severely enough to be rendered incapacitated for one to three days during each menstrual cycle. Primary dysmenorrhoea is where
women suffer from menstrual pain but lack any pathology in their pelvic anatomy. Beta2-adrenoceptor agonists have been used in the
treatment of women with primary dysmenorrhoea but their effects are unclear.
Objectives
To determine the effectiveness and safety of beta2-adrenoceptor agonists in the treatment of primary dysmenorrhoea.
Search methods
We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register; CENTRAL (The Cochrane Library 2011,
Issue 8); MEDLINE; EMBASE; PsycINFO and the EBM Reviews databases. The last search was on 22 August 2011.
Selection criteria
Randomised controlled trials comparing beta2-adrenoceptor agonists with placebo or no treatment, each other or any other conventional
treatment in women of reproductive age with primary dysmenorrhoea.
Data collection and analysis
Two review authors independently assessed trial quality and extracted the data.
Main results
Five trials involving 187 women with an age range of 15 to 40 years were included. Oral isoxsuprine was compared with placebo in
two trials; terbutaline oral spray, ritodrine chloride and oral hydroxyphenyl-orciprenalin were compared with placebo in a further three
trials. Clinical diversity in the studies in terms of the interventions being evaluated, assessments at different time points and the use of
different assessment tools mitigated against pooling of outcome data across studies in order to provide a summary estimate of effect for
any of the comparisons. Only one study, with unclear risk of bias, reported pain relief with a combination of isoxsuprine, acetaminophen
and caffeine. None of the other studies reported any significant clinical difference in effectiveness between the intervention and placebo.
Adverse effects were reported with all of these medications in up to a quarter of the total number of participants. They included nausea,
vomiting, dizziness, quivering, tremor and palpitations.
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Authors’ conclusions
The evidence presented in this review was based on a few relatively small-sized studies that were categorised to have unclear to high risk
of bias, which does not allow confident decision-making at present about the use of beta2-adrenoceptor agonists for dysmenorrhoea.
The benefits as reported in one study should be balanced against the wide array of unacceptable side effects documented with this class
of medication. We have emphasised the lack of precision and limitations in the reported data where appropriate.
P L A I N L A N G U A G E S U M M A R Y
Beta2-adrenoceptor agonists for primary dysmenorrhoea
As many as 50% of premenopausal women regularly suffer from menstrual pain. Many of these women may be incapacitated for one
to three days during each menstrual cycle. Primary dysmenorrhoea (PD) is where women suffer from menstrual pain but lack any
pathology in their pelvic anatomy. A wide range of treatments are available and some of these, such as beta2-adrenoceptor agonists,
have been used to treat women with primary dysmenorrhoea but their effects are unclear. Five studies involving 187 females with an
age range of 15 to 40 years were included in this review. Oral isoxsuprine was examined in two studies; terbutaline oral spray, ritodrine
chloride and oral hydroxyphenyl-orciprenalin were compared with placebo in a further three studies. All of the studies were conducted
over 30 years ago and none were of high quality. None of these medications, other than isoxsuprine combined with acetaminophen
and caffeine, were reported to have any beneficial effect. Side effects with these medications were reported in up to a quarter of the
participants and included nausea, vomiting, dizziness, quivering, tremor and palpitations. At present there is insufficient evidence to
allow confident decision-making about the use of beta2-adrenoceptor agonists for dysmenorrhoea.
B A C K G R O U N D
Dysmenorrhoea refers to painful cramps of uterine origin which
occur during menstrual periods. The effects of dysmenorrhoea
can be debilitating and it is considered to be one of the leading
causes of absenteeism from work and school (Hillen 1999; Klein
1981). Interventions that can provide relief from the distressing
symptoms that cyclically affect many women of reproductive age
could also have a direct bearing on the socioeconomic impact of
this condition.
Description of the condition
Prevalence and aetiology
Dysmenorrhoea is a common gynaecological complaint that can
affect as many as 50% of premenopausal women, 10% of whom
suffer severely enough to be rendered incapacitated for one to
three days during eachmenstrual cycle (Banikarim 2000; Dawood
1990).
It can be classified as either primary or secondary.
• Primary dysmenorrhoea (PD) is where women suffer from
menstrual pain but lack any pathology in their pelvic anatomy.
• Secondary dysmenorrhoea involves a pathological
condition (e.g. ovarian cysts, genital lesions) identifiable in the
pelvic anatomy (Proctor 2005).
Pathogenesis
Primary dysmenorrhoea (PD) often starts during adolescence, at
six to 12 months after menarche (onset of menstruation) and as
soon as ovulatory cycles are established. The duration of pain
is usually 48 to 72 hours in a cycle and is associated with the
menstrual flow.
The prevalence of PD is highest in adolescent women. Estimates
of prevalence range from 20% to 90% (Coco 1999; Strinic 2003),
and up to 60% in an adolescent population (aged 12 to 17 years)
(Klein 1981). A study in Sweden reported dysmenorrhoea in 90%
of women younger than 19 years of age and in 67% of women
aged 24 years and above (Svanberg 1981). This wide range in the
prevalence is most likely due to under reporting of symptoms be-
cause many women self-medicate at home and do not seek med-
ical attention. It may also be attributed to differences in criteria
used and the lack of standard methods for assessing the severity of
dysmenorrhoea (Jamieson 1996).
Risk factors for dysmenorrhoea include:
• positive family history (mother or other female siblings);
2Beta2-adrenoceptor agonists for dysmenorrhoea (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• young age at menarche;
• long menstrual periods with heavy flow;
• smoking;
• obesity;
• alcohol consumption (Andersch 1982; Harlow 1996;
Parazzini 1994).
Some studies have reported that physical activity and the duration
of the menstrual cycle do not correlate with increased menstrual
pain (Andersch 1982).
Clinical signs, symptoms
The cramping pain of dysmenorrhoea, which occurs during men-
struation (monthly bleeding), tends to be localised to the lower ab-
domen but may also radiate to the lower back or thighs (Dawood
2006). Other associated symptoms are nausea, vomiting, diar-
rhoea, headache, fatigue, nervousness and dizziness. The pain can
vary from mild to incapacitating, with 32.9% reporting levels as
mild, 49.7% as moderate, and 17.4% of sufferers as severe (Ortiz
2009). Symptoms begin shortly before or at the onset of menses
and gradually subside over one to three days.
There is growing evidence that the pathogenesis of PD is at-
tributable to prostaglandin F2-alpha (PGF2-alpha), a potent my-
ometrial (uterine muscle) stimulant and vasoconstrictor (contract-
ing blood vessel smooth muscle). PGF2-alpha is present in the se-
cretory endometrium and is capable of enhancing uterine contrac-
tions, leading to pain (Coco 1999). The response to prostaglandin
inhibitors in patients with dysmenorrhoea supports the asser-
tion that dysmenorrhoea is prostaglandin mediated; and elevated
prostaglandin levels found in the endometrial fluid of dysmenor-
rhoeic women have also been correlated with pain (Eden 1998).
The increased levels of prostaglandin in the endometrium follow-
ing the drop in progesterone in the late phase of the menstrual
cycle result in increased myometrial tone and excessive uterine
contraction (Dawood 1990).
Description of the intervention
The beta2-adrenoceptor agonist group of drugs is commonly used
for the relief of bronchospasm in patients with asthma, for moder-
ate attacks of dyspnoea and in chronic obstructive pulmonary dis-
ease (COPD). These medications have also been found useful in
obstetrics because of their effects on the uterine smoothmuscle and
in delaying the onset of premature labour. Drugs in this category
include salbutamol, bitolterol mesylate, formoterol, isoxsuprine,
isoprenalin, levalbuterol, metaproterenol, salmeterol, terbutaline
and ritodrine (Souney 1983). Common side effects associatedwith
some of these drugs include tremor, agitation, headache and pal-
pitations.
How the intervention might work
Treatment options for dysmenorrhoea
A range of treatment options are available, a number of which are
the subject of a Cochrane systematic review (Proctor 2007).
1. Analgesics and nonsteroidal anti-inflammatory drugs
(NSAIDs)
NSAIDs are well established as first-line therapy for primary dys-
menorrhoea (Marjoribanks 2010). They have a direct analgesic ef-
fect through inhibition of prostaglandin synthesis and are capable
of decreasing the volume of menstrual flow. However, whilst their
effectiveness has been considered in several reviews (Weaver 2001;
Zhang 1998) it has been reported that more than 20% of dys-
menorrhoeic women fail to respond to NSAID therapy (Dawood
2006).
2. Oral contraceptives
Off-label use of oral contraceptive pills (OCP) is a recognised
treatment option for dysmenorrhoea (Hendrix 2002), however
a Cochrane systematic review (Wong 2009) found insufficient
evidence from randomised controlled trials to draw conclusions
about the effectiveness of OCP in treating dysmenorrhoea.
3. Other medications and modalities of treatment
These include thiamine, vitamin E, omega-3 fatty acids, magne-
sium, acupuncture, acupressure, various herbal medicines, trans-
dermal nitroglycerin, calcium-channel blockers (Andersson 1978),
beta-adrenergic agonists (kerlund 1976), anti-leukotrienes and the
use of transcutaneous electrical nerve stimulation (TENS). Use
of topical, continuous, low-level heat has also been shown to be
beneficial for some women (Akin 2004). Laparoscopic presacral
neurectomy (PSN) or uterosacral nerve ablation (LUNA) (Latthe
2007) have been used to treat refractory cases of dysmenorrhoea
and have provided a measure of relief for some women for as long
as 12 months after treatment.
It has been suggested that beta2-adrenoceptor agonists work
through a process of increasing blood flow to uterine muscle and
in reducing myometrial activity (kerlund 1976). Binding to the
beta2-adrenergic receptors causes a rise in the intracellular concen-
tration of the second messenger cyclic adenosine monophosphate
(cAMP), which mediates some of the intracellular events result-
ing in relaxation of uterine muscle and alleviation of the pain or
cramps of dysmenorrhoea (Andersson 1982; Revuelta 1999).
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Why it is important to do this review
Beta2-adrenoceptor agonists have been used in the treatment of
women with primary dysmenorrhoea but their effects are unclear.
This systematic review sought to assess the clinical effectiveness
and safety of this group of medicines for primary dysmenorrhoea.
O B J E C T I V E S
To determine the effectiveness and safety of beta2-adrenoceptor
agonists in the treatment of primary dysmenorrhoea.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Inclusion criteria
Women of reproductive age (15 to 49 years) with:
• primary dysmenorrhoea (i.e. no identifiable pelvic
pathology as indicated by pelvic examination, ultrasound scans
or laparoscopy) and self-reported pain during the majority of the
menstrual cycles or for three consecutive menstrual cycles; or
moderate to severe primary dysmenorrhoea (pain that does not
respond well to analgesics, affects daily activities or has a high
baseline score on a validated pain scale).
Exclusion criteria
Participants diagnosed with secondary dysmenorrhoea (for exam-
ple associated with fibroids, endometriosis); dysmenorrhoea re-
sulting from the use of an intrauterine device (IUD); or with mild
or infrequent dysmenorrhoea.
Types of interventions
Beta2-adrenoceptor agonists (any dose, frequency, duration and
route of administration) in the treatment group versus placebo
or no treatment; or against each other or any other conventional
treatment. Examples of beta2-adrenoceptor agonists are described
under ’Description of the intervention’. We also included any of
these interventions if they were used as an add-on or secondary to
conventional therapy.
Concomitant medications or alternative treatments such as diet,
exercise and other modalities were permitted provided they were
equally available to both treatment groups.
Types of outcome measures
Primary outcomes
1. Proportion of women reporting improvement in pain or
discomfort, or both (severity measured using any internationally
recognised and validated visual analogue scale (VAS)).
2. Adverse effects including tremor, agitation, headache,
tachycardia, arrhythmias, palpitations, hypokalaemia or any
clinically diagnosed toxicity; and any reported unacceptable
adverse events associated with any of the interventions. These
were to be categorised as mild (not requiring intervention),
moderate (requiring treatment) and severe (life threatening or
requiring hospitalisation).
Secondary outcomes
1. Proportion of women reporting absences from work or
school and the duration (hours and days) of scholastic or work
absenteeism.
2. Quality of life (including patient or parental satisfaction) as
assessed by a validated questionnaire.
3. Requirements for additional medication or modalities of
treatment.
4. Relief of symptoms other than ’cramp’ pain: proportion of
women with relief of symptoms.
5. Time to resolution of all symptoms.
All outcomes were evaluated based on:
• immediate relief (in less than 1 day), where data at 3, 6, 12,
and 24 hrs were analysed separately;
• late relief (over 24 hrs) reported over three consecutive
cycles, according to the study, where end of study data were to be
combined.
Search methods for identification of studies
Electronic searches
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For the identification of studies to be included or considered for
this review, detailed search strategies were developed for each of
the databases to be searched.
The MEDLINE and EMBASE search strategies were combined
with phases 1 and 2 of the Cochrane sensitive search strategy for
RCTs as published in Appendix 5b.2 of the Cochrane Handbook
for Systematic Reviews of Interventions 5.1.0 (updatedMarch 2011)
(Higgins 2011).
We searched the following databases for relevant trials:
• Menstrual Disorders and Subfertility Group Specialised
Register of controlled trials (to 22 August 2011) (see Appendix
1);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2011, Issue 8) (see
Appendix 2);
• MEDLINE (via Ovid) (1966 to 22 August 2011) (see
Appendix 3);
• EMBASE (via Ovid) (1980 to 22 August 2011) (see
Appendix 4);
• PsycINFO (from inception to 22 August 2011) (see
Appendix 5);
• EBM Reviews on 22 August 2011, available at http://
www.libraries.iub.edu/ (see Appendix 6).
The last search was conducted on 22 August 2011.
Searching other resources
Correspondence
The reference lists of the included studies were also examined but
in view of the age of the studies we were unable to contact any
of the investigators to ask for details of additional published and
unpublished trials.
Language
There were no language restrictions on included studies and we
arranged to translate any that were not in the English language.
Data collection and analysis
Selection of studies
Two of us (ZF and VJ) independently assessed the abstracts of
studies identified from the searches. We obtained full copies of all
relevant and potentially relevant studies and those appearing to
meet the inclusion criteria and for which there were insufficient
data in the title and abstract to make a clear decision. The full text
papers were assessed independently by the two review authors and
any disagreement on the eligibility of included studies was resolved
through discussion and consensus or, if necessary, through a third
author (KE). We excluded those records that did not meet the
inclusion criteria and we noted the reasons for their exclusion in
the ’Characteristics of excluded studies’ table.
Data extraction and management
We entered study details into the ’Characteristics of included
studies’ table using RevMan 5 (RevMan 2011) and collected out-
come data using a form designed for this purpose.
Data were extracted independently and in duplicate by two review
authors (ZF and VJ) and only entered into RevMan 5 if there was
consensus; any disagreements were resolved by consulting with a
third review author (MN).
The following details were extracted.
1. Trial methods: (a) method of allocation; (b) masking of
participants, trialists, and outcome assessors; (c) exclusion of
participants after randomisation, proportion of and reasons for
losses at follow-up.
2. Participants: (a) country of origin and study setting; (b)
sample size; (c) age; (d) menstrual history; (e) pregnancy history;
(f ) inclusion and exclusion criteria; (g) education and occupation
history.
3. Intervention: (a) type; (b) concentration, dose and
frequency, route of administration; (c) duration of intervention
and follow-up.
4. Control: (a) type; (b) duration of intervention and follow-
up.
5. Outcomes: (a) primary and secondary outcomes as specified
in the Types of outcome measures’ section of this review,
including any reported adverse effects.
If stated, the sources of funding of the included studies were
recorded.
Assessment of risk of bias in included studies
Two review authors (ZF, VJ) independently assessed risk of bias
using the Cochrane Collaboration’s tool for assessing risk of bias
as described in Section 8.5 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). The gradings were
compared and we discussed and resolved any inconsistencies in
the assessments.
The following domains were assessed as ’low risk of bias’, ’unclear’
(uncertain risk of bias) or ’high risk of bias’:
1. sequence generation;
2. allocation concealment;
3. blinding of participants, personnel;
4. blinding of outcomes assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We have reported these assessments for each individual study in
the ’Risk of bias in included studies’.
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The overall risk of bias of each of the included studies has also
been reported according to the following categories.
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all criteria were met.
• Unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more criteria were assessed as unclear.
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more criteria were not met.
Measures of treatment effect
Where sufficient reliable data were available, odds ratios (OR)
were calculated. For any dichotomous outcome variables reported
in each individual study we would calculate the odds ratio (OR)
using a modified intention-to-treat (ITT) analysis, that is if the
original investigators did not use ITT analysis we would have
considered dropouts to be treatment failures. We would also have
calculated the summary ORs and 95% confidence intervals (CIs)
using the Cochrane Collaboration’s statistical package (RevMan
2011). Numbers needed to treat (NNT) and their 95%CIs would
have been calculated from the pooled OR and its 95% CI.
Unit of analysis issues
In studies where outcomes were repeated measures, data for these
outcomes were to be analysed for specific time-points, that is at
the end of the intervention and at short, medium and long term
follow-up. Cross-over studies were eligible for inclusion because
the wash-out period between two cycles was almost a month and
there was no likelihood of carry-over effect. As some trials reported
cross-over design, the log odds ratios and their corresponding stan-
dard errors were calculated and entered into the Cochrane soft-
ware.Where trials mispresented cross-over data as if from a parallel
study, the most conservative results were assumed and entered for
analysis.
Dealing with missing data
We were unable to contact any of the investigators in the included
studies and therefore data have been presented as reported using
an available case population, according to the recommendations
in Chapter 16 of the Cochrane Handbook for Systematic Reviews of
Interventions 5.1.0 (Higgins 2011).
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the characteris-
tics of the studies, the similarity between the types of participants,
the interventions and the outcomes, as specified in ’Criteria for
considering studies for this review’. As there were an insufficient
number of studies comparing similar interventions we did not as-
sess statistical heterogeneity between the studies. Statistical het-
erogeneity would have been assessed using a Chi² test and the I²
statistic, where I² values over 50% indicate moderate to high het-
erogeneity and heterogeneity would be considered significant with
a P value of less than 0.10 (Higgins 2003).
Assessment of reporting biases
The low number of studies included in this review did not per-
mit an assessment of publication bias. If we had identified a suffi-
cient number of trials for inclusion in this review (at least 10), we
would have assessed publication bias according to the recommen-
dations on testing for funnel plot asymmetry as described in Sec-
tion 10.4.3.1 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If we had then identified asymmetry
we would have tried to assess other possible causes and explored
these further in the Discussion section of the review, if appropri-
ate.
Data synthesis
Three of us (ZF, VJ and EvZ) reported the data, as specified in
Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We were unable to enter any data in
a meta-analysis, but if a sufficient number of trials were identified
the following methods would have been applied. For the synthesis
andmeta-analysis of any quantitative data, wewould have used the
fixed-effect model if we established that each study was estimating
the same treatment effect, otherwise the random-effects model
would have been used.
Subgroup analysis and investigation of heterogeneity
Lack of data did not permit a subgroup analysis but if further data
were available we planned to carry out subgroup analyses based on
the following categories: age, years after menarche and gestational
status.
Sensitivity analysis
If a sufficient number of studies had been included, we would
have undertaken sensitivity analyses to assess the robustness of our
review results by repeating the analysis with the following adjust-
ments: exclusion of studies with unclear or inadequate allocation
concealment, blinding of outcomes assessment and completeness
of follow-up.
R E S U L T S
Description of studies
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See: ’Characteristics of included studies’ and ’Characteristics of
excluded studies’.
Results of the search
The electronic searches retrieved 144 references to studies. After
examination of the titles and abstracts of these references, all of
the studies which did not match our inclusion criteria and were
clearly ineligible were eliminated from the review. Full text copies
of the seven remaining potentially eligible trials were obtained and
subjected to further evaluation. One (Gallegos-Torres 1975) had
been republished in the Spanish language as Flores-Mercado 1975
and a further study (Akerlund 1976) was excluded as it was not
a randomised controlled trial. One of the included studies, which
was in the Danish language (Andersen 1977), was translated using
Google translate (http://translate.google.com.bh).
For further details see the ’Study flow diagram’ (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Five studies, all of which had been conducted more than 30 years
ago, were included in this review. All five were placebo-controlled.
Two (Gallegos-Torres 1975; Hansen 1975) were randomised par-
allel group trials and the other three (Andersen 1977; Kullander
1981; Nesheim 1976) were randomised but included a cross-over
design. One of the studies (Gallegos-Torres 1975) evaluated both
the preventive and therapeutic effects of the intervention but on
separate subsets of participants. This has been entered into the
comparisons as two separate studies.
Characteristics of the trial setting and investigators
One study (Gallegos-Torres 1975) was conducted in Mexico and
the remaining four in Scandinavia. Two studies were conducted
in Denmark: Hansen 1975 in a university hospital setting and
Andersen 1977 in a county hospital; a general hospital in Sweden
was the setting for Kullander 1981; and Nesheim 1976 was con-
ducted in a university hospital in Norway.
Characteristics of the participants
A total of 187 women with an age range of 15 to 40 years were
included. Gravidity and parity of the participants varied between
studies; all were nulliparous in Andersen 1977, Hansen 1975 and
Nesheim1976; two-thirds in Kullander 1981; and just over half in
Gallegos-Torres 1975. The duration of a history of primary dys-
menorrhoea was not reported in Andersen 1977, Gallegos-Torres
1975, Hansen 1975 or Nesheim 1976 but the participants in
Kullander 1981 had severe essential dysmenorrhoea for more than
one year. The onset, duration, severity and range of symptoms
varied between the participants and across the studies. Participants
in one study (Andersen 1977) reported symptoms which occurred
over time periods ranging from 12 hours to five days, and half of
these were absent from work for at least one day each month. In
Gallegos-Torres 1975 the participants had symptoms which per-
sisted from one to 10 days and in Kullander 1981 from one to
two days; no details were reported in Hansen 1975 other than that
participants spent an unspecified number of days in bed during
the course of each cycle. In Nesheim 1976 just over half of the
participants had severe dysmenorrhoea, most of whom stayed in
bed for one day each menstrual cycle and required analgesic med-
ication for their symptoms.
Characteristics of the interventions
In two of the studies participants received isoxsuprine orally, over
four (Gallegos-Torres 1975) and two (Nesheim 1976) consecu-
tive cycles. A combination of isoxsuprine (10 mg), acetaminophen
(250 mg) and caffeine (30 mg) twice daily, or more as required,
was given for one week prior to menstruation in the ’prophylaxis’
group and until the appearance of symptoms associated with men-
struation in the ’therapy’ group (Gallegos-Torres 1975). Partici-
pants in Nesheim 1976 received isoxsuprine (20 mg x 3) prior to
menstruation and “for as many days as they usually had pain”.
Oral hydroxyphenyl-orciprenalin (3 mg) followed by a further
dose at 30 mins, repeated three to six hourly as required, was pro-
vided over four consecutive cycles in Hansen 1975. Six intraoral
inhalations of terbutaline (1.5 mg) every 3 min up to 6 times/day
during menstrual pain were used over one cycle and then the par-
ticipants crossed-over to placebo for the following cycle (Kullander
1981). In Andersen 1977 the participants received ritodrine chlo-
ride (10 mg) four times daily or placebo to be taken whilst symp-
toms lasted and were crossed over at the next cycle, for a “total
of 60 menstrual cycles”. The type and quantity of concomitant
analgesic or other permissible medications taken during all of the
trials was either unclearly reported or not reported at all.
Characteristics of the outcome measures
All of the included studies evaluated and reported the primary out-
come for this review, that is improvement in pain or discomfort,
but these assessments were carried out at different time-points,
with a range of assessment tools and reported inconsistently across
the studies. Most of these assessments were made using ordinal
scales or simple questionnaires, rather than standard internation-
ally recognised generic or disease specific pain scales or visual ana-
logue scales (VAS), none of which appear to have been piloted,
tested or validated.
In Gallegos-Torres 1975, although baseline data reported the “na-
ture of pain” and its duration, changes to these were not reported as
outcome measures. The “time in which symptoms were relieved”
was recorded as a final evaluation at the end of four consecutive
cycles but the investigators provided very limited details of these
assessments or the tools used. The reliability of any such assess-
ment, based on the possible scaling responses of “excellent, very
good, fair, poor” which were available in this instrument, needs to
be set in the context of specific concerns about its face and content
validity.
Neither the method or assessment tool used nor the timing of
any assessment of pain was reported in Hansen 1975 or Kullander
1981. The resolution of pain in Nesheim 1976 was rated simply
as “some relief ” or “complete relief ” but nothing was reported on
how or when this evaluation was undertaken. In Andersen 1977,
outcomeswere reported as “assessments of the effects of treatment”
(as translated) and rated on a 4-point ordinal scale ranging fromno
improvement, significant improvement to completely pain free,
but the timing of these assessments was not reported.
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All of the studies noted some of the side effects experienced as a
result of the interventions but in most instances these were inad-
equately reported.
Very few of our secondary outcomes were considered in the in-
cluded studies. Although it was reported that many of the partic-
ipants experienced symptoms severe enough to cause absenteeism
from work, no data were collected or reported for any of these in
any of the studies. No assessments of change or improvement in
‘quality of life’ as a result of the interventions were carried out. The
requirement for additional or concomitant medication was only
reported in Kullander 1981, as “some supplementary analgesics”,
but without any indication of the type, strength, quantity and
timing of the use of the medication. The time to resolution of all
symptoms was assessed and reported in only one of the included
studies (Gallegos-Torres 1975) but in three specific time frames:
within the first four hours, 24 hours and between 24 and 48 hours.
Excluded studies
One study (Akerlund 1976) was excluded (see ’Characteristics of
excluded studies’).
Risk of bias in included studies
We assessed each of the included studies for risk of bias and have
reported the judgements for each of the individual domains in
the ’Assessment of risk of bias in included studies’. These are also
presented in the ’Risk of bias’ graph in Figure 2 and the ’Risk of
bias’ summary in Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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The overall risk of bias was assessed in each study, and two of
the studies (Gallegos-Torres 1975; Kullander 1981) included in
this review were categorised as having ’unclear risk of bias’ (plau-
sible bias that raises some doubt about the results) because one
or more criteria were assessed as ’unclear’. The remaining three
studies (Andersen 1977; Hansen 1975; Nesheim 1976) were cate-
gorised as at ’high risk of bias’ (plausible bias that seriously weakens
confidence in the results) because one or more domain received a
judgement of ’high risk’.
These assessments were to a certain extent based on the inadequate
reporting of the criteria that are a prerequisite in the evaluation
of methodological rigour in terms of trial design and conduct.
Concealment of the allocation sequence and blinding are key do-
mains in the assessment of risk of bias and most of the studies pro-
vided insufficient detail to enable accurate judgements to bemade.
Protocol deviation, losses to follow-up with incomplete data and
subsequent per protocol analyses were other important sources of
potential bias in the included studies.
Allocation
Themethods used to generate the allocation sequence and how the
sequence was concealed, such that participants and investigators
enrolling participants could not foresee the upcoming assignment,
are the most important and sensitive indicators that bias has been
minimized in a clinical trial (Schulz 1995).
Sequence generation
The method used to generate the allocation sequence in order
to allow an assessment of whether it would produce comparable
groups was inadequately reported in all of the studies, which there-
fore received a judgement of ’unclear’ for this domain.
Allocation concealment
Inadequate reporting in all of the studies did not allow an assess-
ment to be made on whether adequate measures were taken to en-
sure that investigators were unaware of the upcoming assignment.
Therefore, we judged this domain as ’unclear’ risk of bias for all
of the included studies.
Blinding
Two of the reports (Gallegos-Torres 1975; Hansen 1975) did not
provide sufficient information, other than that the studies were
“double blind”, to enable a clear assessment of whether adequate
and effective measures were used to blind study participants and
personnel from knowledge of which intervention a participant re-
ceived. The three remaining studies (Andersen 1977; Kullander
1981; Nesheim 1976) reported that the interventions were of
“identical appearance”, which indicated that the intended blind-
ing was probably effective and therefore judgements of ’low risk’
of performance bias were given to these studies. All of the out-
comes assessments reported in the included studies were carried
out by the participants. In three of the studies (Andersen 1977;
Kullander 1981; Nesheim1976) the participants appeared to have
been effectively blinded and therefore this domain in these studies
was judged as ’low risk’ of detection bias, whereas in the two other
studies it was assessed as ’unclear’ risk of bias.
Incomplete outcome data
In Gallegos-Torres 1975 all 80 participants contributed outcome
data so we judged this domain as ’low risk’ of bias. Although in
Kullander 1981 one patient “discontinued treatment because of
side effect”, the data appeared to be otherwise complete for each
main outcome and this domain was judged ’low risk’ of bias. In
three of the studies (Andersen1977;Hansen1975;Nesheim1976)
protocol violations or withdrawals and missing outcome data in
addition to per protocol analyses represented a ’high risk’ of bias
for this domain.
Selective reporting
The study protocol was not available for any of the included stud-
ies but in two of the reports (Hansen 1975; Kullander 1981) the
outcomes sought were not clearly specified in the methods sec-
tion, which did not permit a clear judgement of risk of bias to be
made for this domain in these studies. In the remaining studies
all outcomes specified in the methods section appeared to have
been reported fully, with no evidence of selective reporting, and
the studies were judged ’low risk’ of bias for this domain.
Other potential sources of bias
Poorly defined study outcomemeasures and a lack of clarity in their
assessment were some of the other potential threats to the validity
of the included trials that were not addressed by the other domains
in this risk of bias assessment tool. Although the investigators did
not indicate any sources of study support or sponsorship, or declare
any conflicts of interest, some study medications were supplied
by pharmaceutical manufacturers. There was no evidence of any
untoward influence on the design, conduct or analysis in any of
the included studies.
In Kullander 1981, results from the cross-over study were mis-
reported as if it they had arisen from a parallel group trial. In
Gallegos-Torres 1975, although not described as a within-partici-
pant comparison, it looks most likely that a similar error occurred.
We judged this domain as ’unclear’ risk of bias for both studies.
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Effects of interventions
All of the studies included in this review were categorised as ei-
ther ’unclear’ or ’high’ risk of bias and therefore caution is advised
in the interpretation of their findings and in the extrapolation of
the effects of the interventions to clinical decision-making. Two
studies evaluated the effects of orally administered isoxsuprine
compared with placebo (Gallegos-Torres 1975; Nesheim 1976).
Terbutaline spray as an oral inhalation was compared with placebo
in a cross-over study (Kullander 1981); and in the remaining stud-
ies, ritodrine chloride (Andersen 1977) and oral hydroxyphenyl-
orciprenalin (Hansen 1975) were compared with placebo.
Clinical diversity in the studies in terms of the interventions being
evaluated, assessments at different time-points and the use of dif-
ferent assessment tools mitigated against pooling of outcome data
across studies in order to provide a summary estimate of effect for
any of the comparisons. We have presented outcomes in a narra-
tive fashion and emphasised the limitations and lack of precision
in the reported data where appropriate.
(1) Comparison of oral ritodrine chloride with
placebo
One study evaluated this comparison (Andersen 1977) and re-
ported two primary outcomes but none of the secondary out-
comes.
Primary outcomes
Proportion of women reporting improvement in pain or
discomfort
Athough the investigators reported that there was no statistically
significant difference in improvement in ’effects’ between the two
groups (author stated P value = 0.89), the data for the two periods
in this cross-over study were inadequately reported and analysed.
Albeit the potential impact of any cross-over or period effect is
unclear, these were not addressed in the data analysis in this study.
Furthermore, the lack of data in this study did not permit its
reanalysis or the calculation of an effect estimate, and therefore
these have not been reported.
Adverse effects
Nine participants in the ritodrine group reported palpitations and
tremors, and two in the placebo group experienced mild palpita-
tions.
Secondary outcomes
No data were reported.
(2) Comparison of oral isoxsuprine combined with
acetaminophen and caffeine with placebo
One study (Gallegos-Torres 1975) evaluated this comparison and
reported the two primary outcomes and one of the secondary
outcomes.
Primary outcomes
Proportion of women reporting improvement in pain or
discomfort
This outcome was rated as excellent, very good, fair or poor based
on time to complete resolution, rather than change in severity of
symptoms, expressed as the measure of degree of improvement.
In the prophylaxis and therapy studies, up to 95% and 92.5% of
the participants reported improvement with isoxsuprine whereas
40% and 42.5% reported improvement with the placebo, respec-
tively. For estimated effect size, the odds of having an ’excellent’
or ’very good’ outcome were compared assuming the most con-
servative estimate from a paired comparison that was compatible
with the presented tables for each of the prophylaxis and therapy
trials. This corresponded to assuming that none of the two and
three participants, respectively, without a good outcome on active
therapy also failed to have a good outcome on placebo (OR 11.94,
95% CI 2.01 to 71.06 for prophylactic comparison; OR 5.64,
95% CI 1.31 to 24.06 for therapeutic comparison; Analysis 1.1,
Figure 4).
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Figure 4. Forest plot of comparison: 1 Beta2-adrenoceptor agonist versus placebo, outcome: 1.1 Reduction
in pain.
Adverse effects
Nausea and vomiting were the only side effects with the interven-
tion, which occurred in the prophylaxis study in 15% of partici-
pants and in the therapy study in 10% of the participants.
Secondary outcomes
Time to resolution of symptoms
Where symptom resolution was rated as ’excellent’ in the prophy-
laxis group, symptoms were relieved within the first four hours
in 72.5% of those who received oral isoxsuprine compared with
22.5% receiving placebo. In the therapy group this was 70% of
those treated with isoxsuprine; and none in the placebo group.
(3) Comparison of oral isoxsuprine with placebo
One study (Nesheim 1976) evaluated this comparison and re-
ported the two primary outcomes but none of the secondary out-
comes for this review.
Primary outcomes
Proportion of women reporting improvement in pain or
discomfort
Only 8/26 participants had “some relief ” of symptoms with isox-
suprine compared to 5/26 with placebo (OR 1.75, 95% CI 0.41
to 7.47; Analysis 1.1). The data for the two periods in this cross-
over study were inadequately reported and analysed. Albeit the
potential impact of any cross-over or period effects is unclear, these
were not addressed in the data analysis in this study.
Adverse effects
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Almost 20% (5/26) of the participants experienced some side ef-
fects whilst on isoxsuprine. The reported side effects in the isox-
suprine group were dizziness, quivering, nausea and headache.
Secondary outcomes
No data were reported.
(4) Comparison of oral hydroxyphenyl-orciprenalin
with placebo
Only one study evaluated this comparison (Hansen 1975), and
two primary outcomes but none of the secondary outcomes were
reported.
Primary outcomes
Proportion of women reporting improvement in pain or
discomfort
The investigators reported that 10 of the 47 participants (N =
70) who completed the trial in the hydroxyphenyl-orciprenalin
group had a “good effect”, three of whomwere completely relieved
of pain. A similar number (10) in the placebo group achieved a
similar “effect”. However the large number of losses (32%) and
corresponding missing data were not taken into consideration in
the analysis and it was unclear how many participants were ran-
domised in each group (OR 1.00, 95% CI 0.37 to 2.72; Analysis
1.1).
Adverse effects
Almost half (25) of the participants experiencedpalpitationswhilst
receiving hydroxyphenyl-orciprenalin.
Secondary outcomes
No data were reported.
(5) Comparison of terbutaline oral inhalations with
placebo
One study evaluated this comparison (Kullander 1981), and two
primary outcomes and one secondary outcome were reported.
Primary outcomes
Proportion of women reporting improvement in pain or
discomfort
The trialists reported that terbutaline provided an “alleviating ef-
fect” for 12 out of 14 participants, and 1 out of 14 participants in
the placebo group. Odds of success were compared using the most
conservative estimate from a paired comparison that was com-
patible with the presented table. This corresponded to assuming
that the participant who responded to placebo failed to respond
to terbutaline (OR 11.94, 95% CI 0.71 to 200.81; Analysis 1.1).
Adverse effects
Slight tremor and palpitations were experienced by three partici-
pants and in one case a flush during the terbutaline period.
Secondary outcomes
Requirements for additional medication
Over half (8) of the participants required supplementary medica-
tion for complete relief of symptoms during the terbutaline period
and almost all (12/14) during the placebo period.
D I S C U S S I O N
Summary of main results
Our comprehensive search for randomised controlled trials which
examined the effects of the interventions specified in the proto-
col for this review identified a number of trials. In one of these
the investigators endorsed the effectiveness of a combination of
isoxsuprine with acetaminophen and caffeine but provided very
limited and poor quality outcome data to substantiate these claims
(Gallegos-Torres 1975). We were unable to obtain adequate data
frommost of the trials and we summarise only the results from our
analysis of several of the outcomes from these trials. The results in
the other study investigating isoxsuprine (Nesheim 1976) failed to
show any benefit; as was the case in the remaining studies, which
evaluated ritodrine (Andersen 1977), hydroxyphenyl-orciprenalin
(Hansen 1975) and terbutaline (Kullander 1981). Adverse effects
with all of these medications were reported in up to a quarter of
the total number of participants and included nausea, vomiting,
dizziness, quivering, tremor and palpitations.
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Overall completeness and applicability of
evidence
This review included five trials, most of which were conducted
over 30 years ago and whilst they did not provide any reliable
evidence to support the effectiveness of these interventions they
did report some of their undesirable side effects.
Quality of the evidence
Limitations in study design and implementation
Although the study design in the included studies appeared to
have been at best adequate, our study-level assessments of the risk
of bias for a number of the domains in several of these studies
revealed some of the limitations in their implementation. These
have been reported in the ’Risk of bias in included studies’ section
of this review.
Inconsistency of results
One of the included studies (Gallegos-Torres 1975), which was
also republished as Flores-Mercado 1975, reported consistent and
positive effects for isoxsuprine that were more positive than the
conclusions reached in Nesheim 1976. Other than the duplicate
publication of the Gallegos-Torres 1975 study, and based on its
over positive results, one might question the apparent lack of fol-
low-up studies by the trialists to further confirm their results.
Indirectness of evidence
The evidence for effectiveness is somewhat limited and is focused
on a comparison of the effects of beta2-adrenoceptor agonists ver-
sus placebo. We do not have any direct evidence on the compar-
ative effectiveness of any of the beta2-adrenoceptor agonists and
we did not attempt to conduct any indirect comparison (network
meta analysis) to extrapolate the potential comparative effective-
ness of different beta2-adrenoceptor agonists against each other.
The participants in the included studies were in general a repre-
sentative sample, as defined in the inclusion criteria, and therefore
we did not have any significant concerns about the directness of
participants identified in the review. All of the included studies
matched the eligibility criteria for this review. Four studies were
conducted in hospital settings in European countries (Denmark,
Sweden and Norway) and only one of them was conducted in a
developing country (Mexico), in which the setting was not spec-
ified. This may be an issue for consideration by guideline groups
that develop guidelines for populations in a primary care setting
in developing countries. However, it should be kept in mind that
downgrading the evidence for differences in populations is not
recommended except if there are important reasons indicating that
these differences might result in substantial changes in the mag-
nitude of effect of the intervention (Guyatt 2011).
Imprecision of results
The small number and poor quality of the studies that were in-
cluded in this review did not provide any data which could appro-
priately be pooled and therefore any substantive assessment of the
degree of precision of effect was not feasible. We have exercised
caution when extracting and reporting data from the primary re-
search studies and have indicated, where appropriate, any uncer-
tainty with the reliability of the data and any conclusions which
can be made from them.
Publication bias
Although it would be reasonable to assume that the comprehen-
sive electronic searches employed in this review will have identi-
fied all existing randomised controlled trials, and thereby helped
to limit bias in the conduct of this review, the absence of any other
published trials over the intervening 25 years and the scant con-
tribution of the five included trials to the outcomes specified for
this review might be a cause for concern about publication bias.
Moreover, even though only a small number of trials were iden-
tified and an assessment of publication bias could not be made,
one cannot safely discount the possible existence of some unpub-
lished studies with either similar, that is null to negative, results or
reporting additional side effects.
Potential biases in the review process
We made every attempt to limit bias in the review process by en-
suring a comprehensive search for potentially eligible studies. The
authors’ independent assessments of eligibility of studies for in-
clusion in this review and the extraction of data from the included
studies minimized the potential for additional bias beyond that
detailed in the ’Risk of bias in included studies’ tables. The in-
completeness of some of the reports and our inability to obtain
clarification of certain trial details or to resolve ambiguities in the
reports may have contributed to some bias in their assessment.
Where these conditions applied this was explicitly stated in the
text of our review. The effects of language bias on the identifi-
cation and selection of studies is widely recognised and therefore
we ensured that any studies that were not in the English language
were translated so that they could be assessed for eligibility and
risk of bias.
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Agreements and disagreements with other
studies or reviews
We are unaware of any other published systematic reviews or any
additional studies assessing the effectiveness of these interventions.
We have examined several evidence supported guidelines on the
management of dysmenorrhoea, none of which considered beta2-
adrenoceptor agonists.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence presented in this review, which was based on a few
relatively small-sized studies categorised as having unclear to high
risk of bias, does not allow confident decision-making about the
use of beta2-adrenoceptor agonists for dysmenorrhoea. However,
although these studies may have reported a measure of pain relief
and somewhat limited clinical improvement in some of the par-
ticipants these should be balanced against the wide array of un-
acceptable side effects that have been documented with this class
of medications. This may be a reason why no further studies have
been carried out and most probably why beta2-adrenoceptor ago-
nists are, in general, no longer considered the first-line treatment
for dysmenorrhoea. Until, and if, further evidence becomes avail-
able, clinicians should continue to base their decisions on cur-
rently recommended therapeutic regimens of oral contraceptives
and NSAIDS, and other mainstays of treatment which include
reassurance and education, some of which have been covered in
other Cochrane reviews.
Implications for research
Although we make no specific recommendations for future re-
search, proof of concept in vitro studies which explore the po-
tential of a transvaginal mode of delivery of terbutaline to limit
systemic side effects may provide additional treatment options
which should be considered in future research on this clinical
topic (Bulletti 2001). If conducted, these trials should be well-de-
signed and adequately deliveredwith subsequent reporting includ-
ing high-quality descriptions of all aspects of methodology. Rigor-
ous reporting needs to conform to the Consolidated Standards of
Reporting Trials (CONSORT) statement (http://www.consort-
statement.org/), which will enable appraisal and interpretation of
results and accurate judgements to be made about the risk of bias
and the overall quality of the evidence. Although it is uncertain
whether reported quality mirrors actual study conduct, it is note-
worthy that studies with unclear methodology have been shown to
produce biased estimates of treatment effects (Schulz 1995). Ad-
herence to guidelines, such as the CONSORT statement, would
help ensure complete reporting.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 1977
Methods Randomised, double-blind placebo-controlled cross-over trial in Denmark. County hos-
pital setting, date unspecified, over a total number of 60 cycles
Participants RANDOMISED: 26, age 15-36 yrs
INCLUSION CRITERIA:
• primary dysmenorrhoea with symptoms requiring regular medication and
resulting in absenteeism from work
• regular cycle
• nulliparous
• no abnormal gynaecological problems i.e. endometriosis, fibromyoma
EXCLUSION CRITERIA:
• using intrauterine contraception or other OCP
• on hormone therapy
DROP OUTS/WITHDRAWALS: 6; pregnancy(1), side effects of the intervention(1),
lost to follow-up (4)
Interventions Interventions delivered over 60 cycles in 20 participants but not reported how many
cycles/participant
INTERVENTION:
• ritodrine chloride (10 mg) qid taken whilst symptoms persist
COMPARISON
• placebo
Crossed-over at the next cycle
Outcomes Timing and frequency of outcome assessment unreported
PRIMARY OUTCOMES:
“a special form” was used to assess the “impact” and “effects of treatment” and side effects
Rating scale: no improvement/improvement/completely pain free
Adverse effects in intervention and control groups were reported
Absenteeism, quality of life and requirement for additional medication unreported
Notes No sponsorship/support or declaration of any conflicts of interest reported. Authors have
not accounted for/explained the cross-over or period effects in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised” Pg 1366.
Comment: Insufficient detail reported
about the method used to generate the al-
location sequence
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Andersen 1977 (Continued)
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during enrolment,
was not reported.
Comment: Insufficient information to per-
mit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” and “tablets identi-
cal” Pg 1366.
Comment: Probably done.
Blinding of outcome assessment (detection
bias)
All outcomes




Review authors judge that the intended
blinding of participants and key personnel
was probably effective and unlikely to in-
troduce bias into the outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Withdrawals/dropouts 6/26
(32%) but number per group, reasons re-
ported only (2/26). Paucity of data and lack
of clarity in its analysis i.e. whether the par-
ticipants were analysed according to the in-
tention-to-treat principle
High risk of bias.
Selective reporting (reporting bias) Low risk Although the study protocol was unavail-
able all outcomes specified in the methods
section appear to have been reported and
there was no evidence of selective reporting
Other bias Unclear risk The outcomes assessments were poorly de-
fined and relevant data inadequately re-
ported, unclear if these may represent con-
cerns about bias not addressed in the other
domains in this tool
Unclear risk of bias.
Gallegos-Torres 1975
Methods Randomised, double-blind placebo-controlled trial in Mexico. Date and setting unre-
ported. Duration of study four consecutive menstrual cycles
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Gallegos-Torres 1975 (Continued)
Participants RANDOMISED: 80, age 16-40 yrs
2 groups of 40: “prophylactic administration and therapeutic administration”
Within groups divided into 20 placebo, 20 drug combination
INCLUSION CRITERIA:
• primary or essential dysmenorrhoea with or without pre-menstrual tension and
no pelvic disease
EXCLUSION CRITERIA:
• secondary dysmenorrhoea (organo-genic/acquired/extrinsic)
• anovulatory cycles
DROP OUTS/WITHDRAWALS: None reported
Interventions Two groups: Prophylactic (A) before onset of symptoms; Therapeutic (B) after the onset
of symptoms
Group A1 active intervention (20). Group A2 placebo (20)
Group B1 active intervention (20). Group B2 placebo (20)
INTERVENTION:




Prophylactic Group (A) 12 hourly or more often if symptoms present, starting one week
before the onset of periods
Therapeutic Group (B) 12 hourly after onset of symptoms in each cycle
Intervention over four consecutive menstrual cycles
Outcomes Final evaluation at the end of four consecutive cycles, but very limited information, how
and in particular which assessment tools were used
PRIMARY OUTCOMES:
• number of participants rated improvement/change: excellent (symptoms
completely relieved); very good (symptoms failed to disappear entirely); fair and poor
(no improvement observed). Severity measured as nature and duration of pain
• adverse effects
SECONDARY OUTCOMES:
• time to resolution of all symptoms
Absenteeism, quality of life and requirement for additional medication unreported
Notes No sponsorship/support or declaration of any conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were distributed at ran-
dom into two groups...” Pg 195.
Comment: Insufficient detail reported
about the method used to generate the al-
location sequence
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Gallegos-Torres 1975 (Continued)
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during enrolment,
was not reported.
Comment: Insufficient information to per-
mit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “ double-blind method...” Pg 194.
Comment: The measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received were not clearly reported
Participants were outcome assessors. Re-
view authors judge it is unclear if the out-
come is likely to be influenced by the lack
of blinding
Insufficient information to permit a clear
judgement. Unclear risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: The measures used to blind
the outcome assessors from knowledge of
which intervention a participant received
were not clearly reported
Outcomes assessment:
• Participant-assessed
Lack of blinding is likely to exert an in-
fluence on outcome measurement, but in-
sufficient detail reported to permit a clear
judgement.
Unclear risk of bias.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of missing or incomplete data
due to attrition or exclusions for the out-
comes reported in the study.
Comment: Low risk of bias.
Selective reporting (reporting bias) Low risk Although the study protocol was unavail-
able all outcomes specified in the methods
section appear to have been reported and
there was no evidence of selective reporting
Other bias Unclear risk There are clearly 80 participants with 40 in
each of the prophylaxis and therapy stud-
ies. However, each study reports results as
if from a parallel trial with 40 in each
treatment group. Although in the meth-
ods section there is no mention of cross-
over design it seems most likely that each
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Gallegos-Torres 1975 (Continued)
study included paired comparison with all
participants receiving both treatment and
placebo: possibly two cycles of each
Insufficient information to permit a clear
judgement. Unclear risk of bias
Hansen 1975
Methods Randomised double-blind placebo-controlled trial inOdenseeUniversityHospital, Den-
mark. Date unreported. Duration of study four consecutive menstrual cycles
Participants Student nurses 17-28 yrs nulliparous
RANDOMISED: N=70, unclear how many to each group
INCLUSION CRITERIA:





• 23/70 (32%) due to protocol violation i.e. use of “additional analgesics or started
hormonal contraception during study” Pg 566
Interventions INTERVENTION:
• oral hydroxyphenyl-orciprenalin (3 mg) followed by a further dose at 30 mins,
repeated 3-6 hourly prn
CONTROL:
• placebo
Four consecutive menstrual cycles
Outcomes Method of assessment and timing unreported
PRIMARY OUTCOMES:




Notes No sponsorship/support or declaration of any conflicts of interest reported
Inadequate and incomplete reporting of essential trial details and missing data places
this study at ’high risk of bias
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The distribution of the drug and
placebo was randomized”. Pg 567.
Comment: Insufficient detail reported
about the method used to generate the al-
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Hansen 1975 (Continued)
location sequence
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during enrolment,
was not reported.
Comment: Insufficient information to per-
mit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”. Pg 566.
Comment: The measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received were not clearly reported
Participants were outcome assessors. Re-
view authors judge it is unclear if the out-
come is likely to be influenced by the lack
of blinding
Insufficient information to permit a clear
judgement.
Unclear risk of bias.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: The measures used to blind
the outcome assessors from knowledge of
which intervention a participant received
were not clearly reported
Outcomes assessment:
• Participant-assessed.
Review authors judge it is unclear if the out-
come assessment is likely to be influenced
by the lack of blinding. Unclear risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “excluded were those who, despite
the instructions given either used addi-
tional and not clearly defined analgesics
or started hormonal contraception during
study”. Pg 566
Comment: Withdrawals/dropouts and
protocol violations (32%) but number per
group and the reasons unreported. Paucity
of data and lack of clarity in its analysis i.e.
whether the participants were analysed ac-
cording to the intention to treat principle
High risk of bias.
Selective reporting (reporting bias) Unclear risk The protocol was unavailable and the re-
ported outcomes were not pre-specified in
the methods section of the study.
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Hansen 1975 (Continued)
Comment: Insufficient information to per-
mit a clear judgement
Other bias Low risk There were no concerns about bias not ad-
dressed in the other domains in this tool
Kullander 1981
Methods Randomised, double-blind placebo-controlled cross-over trial in Sweden. Date unre-
ported, in General Hospital setting. Duration of study two consecutive menstrual cycles
Participants RANDOMISED: N=14, aged 15-39 yrs (mean 27), 10 nulliparous, 4 parous
INCLUSION CRITERIA:
• “severe essential dysmenorrhea for more than one year”. Pg 425
EXCLUSION CRITERIA: none reported
DROP OUTS/WITHDRAWALS: none reported
Interventions Active intervention one menstrual period and crossed-over to placebo for next period
INTERVENTION:
• terbutaline (1.5 mg), six intra-oral inhalations every 3 min up to 6 times/day




therapeutic effect was assessed and graded as none/weak/moderate/good very good at
the end of each menstrual cycle
• pain relief
• adverse effects were recorded
SECONDARY OUTCOMES:
• reported as supplementary analgesia, but no details of type and dosage provided
Absenteeism, quality of life and requirement for additional medication unreported
Notes No sponsorship/support or declaration of any conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were given in random order....”.
Pg 425.
Method used to generate the allocation se-
quence. Unclear if all participants received
active intervention in the first period and
“placebo sprays .....during the next period”
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Kullander 1981 (Continued)
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during enrolment,
was not reported.
Comment: Insufficient information to per-
mit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “sprays of identical appearance....”
Pg 425.
Comment: Probably done.
Blinding of outcome assessment (detection
bias)
All outcomes




Review authors judge that the intended
blinding of participants and key personnel
was probably effective and unlikely to in-
troduce bias into the outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “one patient discontinued treat-
ment because of side effect” Pg 427.
No other losses to attrition or exclusions
were reported, the data appear to have
beenotherwise complete for eachmain out-
come.
Comment: Low risk of bias.
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable and the
outcomes sought were not clearly specified
in themethodswhich did not permit a clear
judgement to be made.
Comment: Unclear risk of bias.
Other bias Unclear risk Although this was a cross-over design the
presented analysis is as if it were a parallel
design with twice as many participants.
Comment: Unclear risk of bias.
Nesheim 1976
Methods Randomised, double-blind placebo-controlled cross-over trial in Oslo Norway. Date and
setting unspecified. Duration of study two consecutive menstrual cycles
Participants RANDOMISED: 30 (29 nulliparous, 1 primiparous), severe (18), moderate (12) dys-
menorrhoea. Age and other demographic details unreported
INCLUSION CRITERIA:
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DROPOUTS/WITHDRAWALS: 4 due to side effects; placebo (1), and (3) intervention
group and reasons not reported
Interventions INTERVENTION:




Two consecutive cycles, one each of active ingredient and placebo and crossed-over for
second cycle
Outcomes Method and timing of assessment unreported, only that the “ participants were ques-
tioned...” Pg 315
PRIMARY OUTCOMES:




Notes No sponsorship/support or declaration of any conflicts of interest reported other than
intervention and placebo supplied by Ferrosan/Norfarma A/S
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The type of tablets taken during
the first cycle was randomized”. Pg 315.
Comment: Insufficient detail reported
about the method used to generate the al-
location sequence
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during enrolment,
was not reported.
Comment: Insufficient information to per-
mit judgement.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “isoxsuprine 20 mg x 3 or placebo
tablets identical in appearance” and “dou-
ble-blind”. Pg 315.
Comment: Probably done.
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Nesheim 1976 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “isoxsuprine 20mg x 3 or placebo




Review authors judge that the intended
blinding of participants and key personnel
was probably effective and unlikely to in-
troduce bias into the outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Twenty six of the participants
completed the trial. One of those who did
not complete did so because of side effects
of the first course of the tablets (which was
placebo), for the other three the reasons
were not related to tablets”. Pg 315
Comment: Although losses to follow up
were reported and small although unbal-
anced, the numbers in each group and rea-
sons, unclear.
Paucity of data and lack of clarity in its
analysis i.e. whether the participants were
analysed according to the intention to treat
principle
High risk of bias.
Selective reporting (reporting bias) Low risk Although the study protocol was unavail-
able all outcomes specified in the methods
section appear to have been reported and
there was no evidence of selective reporting
Other bias Low risk Although medication and placebo were
supplied by the manufacturer there was no
evidence of any influence over the design,
conduct or data analysis in the trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akerlund 1976 Non-RCT
RCT= Randomised controlled trial
OCP= Oral contraceptive pill
prn = pro re nata (when necessary)
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D A T A A N D A N A L Y S E S
Comparison 1. Beta2-adrenoceptor agonist versus placebo




participants Statistical method Effect size










1 Odds Ratio (Fixed, 95% CI) 5.64 [1.32, 24.06]
1.3 oral isoxsuprine versus
placebo
1 Odds Ratio (Fixed, 95% CI) 1.75 [0.41, 7.47]
1.4 oral hydroxyphenyl-
orciprenalin versus placebo
1 Odds Ratio (Fixed, 95% CI) 1.0 [0.37, 2.72]
1.5 terbutaline inhalations
versus placebo
1 Odds Ratio (Fixed, 95% CI) 11.94 [0.71, 200.81]
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Analysis 1.1. Comparison 1 Beta2-adrenoceptor agonist versus placebo, Outcome 1 Reduction in pain.
Review: Beta2-adrenoceptor agonists for dysmenorrhoea
Comparison: 1 Beta2-adrenoceptor agonist versus placebo
Outcome: 1 Reduction in pain
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 prophylactic oral isoxsuprine plus acetaminophen/caffeine versus placebo
Gallegos-Torres 1975 2.48 (0.91) 100.0 % 11.94 [ 2.01, 71.06 ]
Subtotal (95% CI) 100.0 % 11.94 [ 2.01, 71.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
2 therapeutic oral isoxsuprine plus acetaminophen/caffeine versus placebo
Gallegos-Torres 1975 1.73 (0.74) 100.0 % 5.64 [ 1.32, 24.06 ]
Subtotal (95% CI) 100.0 % 5.64 [ 1.32, 24.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
3 oral isoxsuprine versus placebo
Nesheim 1976 0.56 (0.74) 100.0 % 1.75 [ 0.41, 7.47 ]
Subtotal (95% CI) 100.0 % 1.75 [ 0.41, 7.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
4 oral hydroxyphenyl-orciprenalin versus placebo
Hansen 1975 0 (0.51) 100.0 % 1.00 [ 0.37, 2.72 ]
Subtotal (95% CI) 100.0 % 1.00 [ 0.37, 2.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 terbutaline inhalations versus placebo
Kullander 1981 2.48 (1.44) 100.0 % 11.94 [ 0.71, 200.81 ]
Subtotal (95% CI) 100.0 % 11.94 [ 0.71, 200.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Chi2 = 8.80, df = 4 (P = 0.07), I2 =55%
0.01 0.1 1 10 100
Favours placebo Favours beta2-adrenoceptor agonist
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A P P E N D I C E S
Appendix 1. Menstrual Disorders and Subfertility Group (MDSG) Specialised Register
The MDSG search string is dated from inception of database until present.
Keywords CONTAINS “*Dysmenorrhea” or “Dysmenorrhea-Symptoms” or “dysmenorrhoea” or “cyclical pelvic pain” or “primary
dysmenorrhea” or “pelvic pain” or “pain-dysmenorrhea” or “pain-pelvic” or “menstrual distress” or “menstrual pain” or “menstrual
cramps” or “cramping” or Title CONTAINS“*Dysmenorrhea” or “Dysmenorrhea-Symptoms” or “dysmenorrhoea” or “cyclical pelvic
pain” or “primary dysmenorrhea” or “pelvic pain” or “pain-dysmenorrhea” or “pain-pelvic” or “menstrual distress” or “menstrual pain”
or “menstrual cramps” or “cramping”
AND
Keywords CONTAINS “Terbutaline” or “Isoxsuprine” or “beta-adrenoceptor” or Title CONTAINS or “Terbutaline” or “Isoxsuprine”
or “beta-adrenoceptor”
Appendix 2. CENTRAL search strategy




4 (pelvi$ adj5 pain).ti,ab,sh.
5 dysmenorrh$.ti,ab,sh.
6 (cyclic$ adj1 pain$).tw.
7 or/1-6
8 exp Albuterol/











20 7 and 19
Appendix 3. MEDLINE (via Ovid) search strategy




4 (pelvi$ adj5 pain).ti,ab,sh.
5 dysmenorrh$.ti,ab,sh.
6 (cyclic$ adj1 pain$).tw.
7 or/1-6
8 exp Albuterol/
9 exp Adrenergic beta-Agonists/
10 salbutamol.tw.
11 Terbutaline.tw.
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20 randomized controlled trial.pt.
21 controlled clinical trial.pt.
22 randomized.ab.
23 placebo.tw.
24 clinical trials as topic.sh.
25 randomly.ab.
26 trial.ti.
27 (crossover or cross-over or cross over).tw.
28 or/20-27
29 (animals not (humans and animals)).sh.
30 28 not 29
31 7 and 19 and 30
Appendix 4. EMBASE (via Ovid) search strategy
1 exp dysmenorrhea/ or exp menstruation disorder/ or exp pain/
2 dysmenorrh$.tw.
3 (pelvi$ adj5 pain).tw.
4 (painful adj5 menstrua$).tw.
5 (pain$ adj5 period$).tw.
6 (cycl$ adj2 pain$).tw.
7 (menstr$ adj2 cramp$).tw.
8 or/1-7
9 exp beta adrenergic receptor/











21 (beta$ adj2 agonist$).tw.
22 or/9-21
23 8 and 22
24 Clinical Trial/
25 Randomized Controlled Trial/
26 exp randomization/
27 Single Blind Procedure/
28 Double Blind Procedure/
29 Crossover Procedure/
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30 Placebo/





36 (allocated adj2 random).tw.
37 Single blind$.tw.
38 Double blind$.tw.






45 abstract report/ or letter/
46 or/43-45
47 42 not 46
48 23 and 47
49 (201006$ or 201007$ or 201008$ or 201009$ or 201010$ or 201011$ or 201012$).em.
50 2011$.em.
51 49 or 50
52 48 and 51
Appendix 5. PsycINFO search strategy
The PsycINFO search strategy is dated from 1806 until 22 August 2011
1 exp dysmenorrhea/ or exp menstrual disorders/
2 dysmenorrh$.tw.
3 (pelvi$ adj5 pain).tw.
4 (painful adj5 menstrua$).tw.
5 (pain$ adj5 period$).tw.
6 (cycl$ adj2 pain$).tw.
7 (menstr$ adj2 cramp$).tw.
8 or/1-7











20 8 and 19
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Appendix 6. EBM Reviews search strategy
1 dysmenorrh$.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
2 menstru$ disorder$.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
3 (pelvi$ adj5 pain).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
4 (painful adj5 menstrua$).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
5 (painful adj5 period$).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
6 or/1-5
7 salbutamol.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
8 Beta Adrenergic Receptor Stimulating Agent.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
9 or/7-8
10 6 and 9
11 from 10 keep 1
H I S T O R Y
Date Event Description
14 April 2008 Amended converted to new review format
28 February 2002 New citation required and major changes Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The inclusion criteria in the review were amended to include studies where the intervention could have been used as an add-on to
standard treatment. This would then allow for the evaluation of studies which could provide evidence of the effects of the intervention
in unresponsive dysmenorrhoea.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetaminophen [therapeutic use]; Adrenergic beta-2 Receptor Agonists [∗therapeutic use]; Caffeine [therapeutic use]; Dysmenorrhea
[∗drug therapy]; Isoxsuprine [therapeutic use]; Metaproterenol [analogs & derivatives; therapeutic use]; Randomized Controlled Trials
as Topic; Ritodrine [therapeutic use]; Terbutaline [therapeutic use]
MeSH check words
Adolescent; Adult; Female; Humans; Young Adult
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